Published in Obesity and Diabetes Week, August 8th, 2005
According to a study from France, "Fibrates and thiazolidinediones are commonly used for the treatment of dyslipidemia and type 2 diabetes, respectively. The aim of this study was to investigate the effects on body weight as well as on glucose and lipid homeostasis of ligands for PPAR-alpha and PPAR-gamma, fenofibrate, and rosiglitazone, alone or in association."
"Ob/ob mice were divided into four groups: control, and mice daily injected (intraperitoneally), either with 10 mg/kg rosiglitazone, 100 mg/kg fenofibrate, or both molecules," said Maria-Carmen Carmona at Centre...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week